Motor Neuron Disease
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Neurizon TherapeuticsAustralia - Melbourne
2 programs2
MonepantelPhase 11 trial
MonepantelPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UCB PharmaLevetiracetam
Neurizon TherapeuticsMonepantel
Neurizon TherapeuticsMonepantel
Clinical Trials (3)
Total enrollment: 44 patients across 3 trials
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
Start: May 2006Est. completion: Jun 200820 patients
Phase 2Completed
An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease
Start: Feb 2024Est. completion: May 202512 patients
Phase 1Completed
A Study of Monepantel in Individuals With Motor Neurone Disease
Start: Jun 2022Est. completion: Nov 202312 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.